3. Segment information

3. Segment information

Following the sale of the service division on 1 April 2014, the continuing operations relate primarily to R&D activities. Consequently there is one reportable segment.

Geographical information

In 2014 the Group’s R&D continuing operations were located in Belgium, Croatia, France and The Netherlands.

In 2014 the Group’s continuing operations top 10 customers represents 98% of the revenues. The Group’s continuing operations client base includes four of the top 20 pharmaceutical companies in the world in 2014 and 2013.

Following table summarizes Group revenues by destination of customer:

 

Year ended 31 December,

(thousands of €)

2014

2013

United States

31,100

46,963

Europe

38,169

29,662

Asia Pacific

100

 

Total revenues

69,368

76,625

Following table summarizes Group revenues of the continuing operations by destination of Group company:

 

Year ended 31 December,

(thousands of €)

2014

2013

Galapagos NV (Belgium)

65,448

73,913

Galapagos SASU (France)

108

 

Fidelta d.o.o. (Croatia)

3,726

2,514

Xenometrix, Inc. (United States)

86

198

Total revenues

69,368

76,625

In 2014, Galapagos held €57 million of non-current assets (€114 million in 2013) distributed as follows:

  • France: €26 million (€27 million in 2013)
  • Belgium: €25 million (€24 million in 2013)
  • Croatia: €4 million (€4 million in 2013)
  • The Netherlands: €1 million (€2 million in 2013)

The decrease in non-current assets is explained by the sale of the service division located in the United Kingdom which was contributing €57 million of non-current assets in 2013.